SAN DIEGO, CALIFORNIA — Ting Therapeutics has announced that its investigational drug TT004 has received approval to begin clinical testing in China, clearing the way for a Phase Ib study evaluating its potential to protect patients from the harmful effects of cisplatin chemotherapy, including treatment-related hearing loss....
Continue reading at Hearing Health Matters
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change — TT004 is entering Phase Ib (early safety) testing; no efficacy data in humans are yet available.
Cisplatin-induced hearing loss (ototoxicity) remains an unmet clinical need, and any new protective drug entering human trials represents meaningful pipeline progress for audiologists managing oncology patients.
- 01Ting Therapeutics received regulatory approval in China to begin a Phase Ib trial of TT004.
- 02TT004 targets cisplatin-induced ototoxicity (hearing damage from a common chemotherapy drug).
- 03Phase Ib trials primarily assess safety and dosing, not effectiveness.
- 04No human efficacy data for TT004 are available yet.
- 05The trial is conducted under Chinese regulatory authority, limiting direct extrapolation to other markets.
TT004 received regulatory approval in China to begin a Phase Ib clinical trial for cisplatin-induced hearing loss.
press releasesupportedTT004 is designed to protect against cisplatin-induced hearing loss.
press releaseunclear- Publication type
- clinical_trial
- Evidence level
- na
- Population
- Patients receiving cisplatin chemotherapy at risk of ototoxicity
- Intervention
- TT004 investigational drug for otoprotection against cisplatin
Primary outcomes
Safety and tolerability of TT004 (Phase Ib); Dose determination